Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach.

Tytuł:
Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach.
Autorzy:
Ma F; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Wang B; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xue L; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Kang W; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Li Y; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Li W; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Liu H; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Ma S; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Tian Y; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China. .
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Aug; Vol. 146 (8), pp. 2135-2142. Date of Electronic Publication: 2020 Apr 18.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Berlin ; New York : Springer-Verlag.
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Neuroendocrine/*drug therapy
Stomach Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Neuroendocrine/pathology ; Carcinoma, Neuroendocrine/surgery ; Case-Control Studies ; Chemotherapy, Adjuvant ; Female ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Retrospective Studies ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Survival Rate ; Treatment Outcome
References:
Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, Fugazzola P, Tomasoni M, Glehen O, Catena F, Yonemura Y, Ansaloni L (2018) Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. [Journal Article; Meta-Analysis; Review; Systematic Review]. Int J Surg 51:120–127. https://doi.org/10.1016/j.ijsu.2018.01.008. (PMID: 10.1016/j.ijsu.2018.01.00829413875)
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Magic TP (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. [Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. N Engl J Med 355(1):11–20. https://doi.org/10.1056/NEJMoa055531. (PMID: 10.1056/NEJMoa05553116822992)
Das M (2017) Neoadjuvant chemotherapy: survival benefit in gastric cancer. [News]. Lancet Oncol 18(6):e307. https://doi.org/10.1016/S1470-2045(17)30321-2. (PMID: 10.1016/S1470-2045(17)30321-228483410)
Fukuba N, Yuki T, Ishihara S, Sonoyama H, Tada Y, Kusunoki R, Oka A, Oshima N, Moriyama I, Kawashima K, Kinoshita Y (2014) Gastric mixed adenoneuroendocrine carcinoma with a good prognosis. [Case Reports; Journal Article]. Intern Med 53(22):2585–2588. https://doi.org/10.2169/internalmedicine.53.3328. (PMID: 10.2169/internalmedicine.53.332825400179)
Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A (2014) The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. [Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. Int J Surg 12(10):1061–1069. https://doi.org/10.1016/j.ijsu.2014.08.349. (PMID: 10.1016/j.ijsu.2014.08.34925157992)
Hokonohara K, Takata A, Noda T, Imamura H, Hirota M, Oshima K, Tanida T, Hatano H, Komori T, Morita S, Iwazawa T, Akagi K, Adachi S, Dono K (2014) A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy. [Case Reports; English Abstract; Journal Article]. Gan To Kagaku Ryoho 41(12):2287–2289. (PMID: 25731498)
Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Katai H, Tsuda H, Kushima R (2013) Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. [Journal Article; Research Support, Non-U.S. Gov't]. Am J Surg Pathol 37(7):949–959. https://doi.org/10.1097/PAS.0b013e31828ff59d. (PMID: 10.1097/PAS.0b013e31828ff59d23759931)
Laughlin B, Scott A, Goyal U (2019) Pathologic complete response after neoadjuvant chemoradiation in a patient with gastric neuroendocrine cancer. [Case Reports]. Cureus 11(7):e5214. https://doi.org/10.7759/cureus.5214. (PMID: 10.7759/cureus.5214315656186758975)
Lee JH, Kim HW, Kang DH, Choi CW, Park SB, Kim SH (2013) A gastric composite tumor with an adenocarcinoma and a neuroendocrine carcinoma: a case report. [Journal Article]. Clin Endosc 46(3):280–283. https://doi.org/10.5946/ce.2013.46.3.280. (PMID: 10.5946/ce.2013.46.3.280237670403678067)
Li W, Qin J, Sun YH, Liu TS (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. [Journal Article; Meta-Analysis]. World J Gastroenterol 16(44):5621–5628. https://doi.org/10.3748/wjg.v16.i44.5621. (PMID: 10.3748/wjg.v16.i44.5621211051972992682)
Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP (2013) Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. [Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't]. J Gastroenterol Hepatol 28(5):777–782. https://doi.org/10.1111/jgh.12152. (PMID: 10.1111/jgh.1215223425049)
Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW (2017) Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. [Journal Article]. World J Gastroenterol 23(3):516–524. https://doi.org/10.3748/wjg.v23.i3.516. (PMID: 10.3748/wjg.v23.i3.516282100885291857)
Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K, Ohshima K, Urakami K, Yamaguchi K (2017) Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. [Journal Article]. Biomed Res 38(1):19–27. https://doi.org/10.2220/biomedres.38.19. (PMID: 10.2220/biomedres.38.1928239029)
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Et A (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. [Journal Article; Research Support, Non-U.S. Gov't]. Cancer 73(11):2680–2686. https://doi.org/10.1002/1097-0142(19940601)73:11%3c2680:aid-cncr2820731105%3e3.0.co;2-c. (PMID: 10.1002/1097-0142(19940601)73:11%3c2680::aid-cncr2820731105%3e3.0.co;2-c8194005)
de Mestier L, Cros J (2019) Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN). [Journal Article]. Ann Endocrinol (Paris) 80(3):172–173. https://doi.org/10.1016/j.ando.2019.04.006. (PMID: 10.1016/j.ando.2019.04.006)
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA (2020) The 2019 WHO classification of tumours of the digestive system. [Journal Article]. Histopathology 76(2):182–188. https://doi.org/10.1111/his.13975. (PMID: 10.1111/his.1397531433515)
Nakai M, Kawasaki H, Wajima N, Kimura A, Nakayama Y, Muroya T, Yonaiyama S, Okano K, Nagase H, Hakamada K (2013) A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy. [Case Reports; Journal Article]. Gan To Kagaku Ryoho 40(12):2301–2303. (PMID: 24394092)
Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K (2011) Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. [Historical Article; Journal Article]. Gastric Cancer 14(2):161–165. https://doi.org/10.1007/s10120-011-0025-5. (PMID: 10.1007/s10120-011-0025-521327441)
Oneda E, Liserre B, Bianchi D, Rota L, Savelli G, Zorzi F, Zaniboni A (2019) Diagnosis of mixed adenoneuroendocrine carcinoma (MANEC) after neoadjuvant chemotherapy for pancreatic and gastric adenocarcinoma: two case reports and a review of the literature. [Case Reports]. Case Rep Oncol 12(2):434–442. https://doi.org/10.1159/000501200. (PMID: 10.1159/000501200312751346600038)
Onoyama H, Iwasaki Y, Ohashi M, Iwanaga T, Ohinata R, Maeda Y, Omuro Y, Sasaki E, Shimoyama T, Tateishi Y (2011) A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy. [Case Reports; Journal Article; Review]. Gan To Kagaku Ryoho 38(12):2131–2133. (PMID: 22202306)
Park JY, Ryu MH, Park YS, Park HJ, Ryoo BY, Kim MG, Yook JH, Kim BS, Kang YK (2014) Prognostic significance of neuroendocrine components in gastric carcinomas. [Journal Article; Research Support, Non-U.S. Gov't]. Eur J Cancer 50(16):2802–2809. https://doi.org/10.1016/j.ejca.2014.08.004. (PMID: 10.1016/j.ejca.2014.08.00425201164)
Paun I, Becheanu G, Costin AI, Constantin VD, Mihai GM, Radu L, Iovan L, Varcus F (2018) Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system—a review. [Journal Article; Review]. Rom J Morphol Embryol 59(3):673–678. (PMID: 30534804)
Russolillo N, Vigano' L, Razzore P, Langella S, Motta M, Bertuzzo F, Papotti M, Ferrero A (2015) Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. [Comparative Study; Journal Article]. Eur J Surg Oncol 41(6):751–757. https://doi.org/10.1016/j.ejso.2015.02.011. (PMID: 10.1016/j.ejso.2015.02.01125887286)
Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z (2016) Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. [Journal Article]. BMC Gastroenterol 16:111. https://doi.org/10.1186/s12876-016-0505-5. (PMID: 10.1186/s12876-016-0505-5276136575016962)
van der Veen A, Seesing M, Wijnhoven B, de Steur WO, van Berge HM, Rosman C, van Sandick JW, Mook S, Haj MN, Ruurda JP, Brosens L, van Hillegersberg R (2018) Management of resectable esophageal and gastric (mixed adeno) neuroendocrine carcinoma: a nationwide cohort study. [Journal Article]. Eur J Surg Oncol 44(12):1955–1962. https://doi.org/10.1016/j.ejso.2018.07.058. (PMID: 10.1016/j.ejso.2018.07.05830201419)
Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Yang YH, Huang CM (2016) Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. [Journal Article]. Eur J Surg Oncol 42(10):1464–1470. https://doi.org/10.1016/j.ejso.2016.08.004. (PMID: 10.1016/j.ejso.2016.08.00427570115)
Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T (2014) Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. [Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't]. Cancer Sci 105(9):1176–1181. https://doi.org/10.1111/cas.12473. (PMID: 10.1111/cas.12473249755054462387)
Yang G, Li D, Zheng F, Yang L (2018) Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: a case report. [Journal Article]. Mol Clin Oncol 8(5):653–656. https://doi.org/10.3892/mco.2018.1594. (PMID: 10.3892/mco.2018.1594297321535920656)
Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST (2019) The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. [Journal Article]. J Cancer 10(14):3140–3144. https://doi.org/10.7150/jca.30355. (PMID: 10.7150/jca.30355312895846603380)
Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X (2017) Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. [Journal Article; Meta-Analysis; Review]. Oncotarget 8(18):30477–30494. https://doi.org/10.18632/oncotarget.12955. (PMID: 10.18632/oncotarget.1295527802185)
Grant Information:
81772642 National Natural Science Foundation of China; CFH 2018-2-4022 Capital's Funds for Health Improvement and Research
Contributed Indexing:
Keywords: Mixed adenoneuroendocrine carcinoma; Neoadjuvant chemotherapy; Neuroendocrine carcinoma; Stomach
SCR Disease Name:
Adenocarcinoid tumor
Entry Date(s):
Date Created: 20200420 Date Completed: 20200713 Latest Revision: 20210813
Update Code:
20240104
DOI:
10.1007/s00432-020-03214-w
PMID:
32306127
Czasopismo naukowe
Purpose: The impact of neoadjuvant chemotherapy (NAC) on patients with neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) of the stomach is unclear. The aim of this retrospective study was to evaluate the effects of NAC on patients with these conditions.
Methods: This study included patients with locally advanced NEC or MANEC of the stomach who underwent gastrectomy. Histologic and prognostic effects of NAC were assessed. The overall survival (OS) rate was used to compare treatment efficacies between NAC patients and surgery-first patients.
Results: Of the 69 patients included in this study, 20 received NAC and 49 underwent surgery first after diagnosis. A total of 13 patients responded to NAC (including 3 with complete remission and 10 with partial remission) and 7 patients acquired stable disease status according to the Response Evaluation Criteria in Solid Tumors version 1.1. One patient (5%) achieved a pathological complete response after NAC. Pathological tumor regression grades 1, 2, 3, 4, and 5 were observed in 1 (5%), 5 (25%), 3 (15%), 10 (50%), and 1 (5%) patient(s) with NAC, respectively. The incidence of postoperative complications was similar in the two groups. Patients in the NAC group demonstrated better OS than did patients in the surgery-first group (P = 0.032). Multivariate analyses showed that NAC, adjuvant chemotherapy, and the clinical N stage were independent factors affecting OS.
Conclusion: In patients with locally advanced NEC and MANEC of the stomach, NAC significantly improved OS.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies